Semaglutide vs Liraglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Also: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Key Comparison Insights
- Both Semaglutide and Liraglutide are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. | Liraglutide has 97% homology to native GLP-1 with modifications for extended half-life. It slows gastric emptying, increases insulin secretion, suppresses glucagon, and acts on brain appetite centers to reduce hunger. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 1.8-3 mg daily Once daily |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection daily |
| Typical Duration | Long-term / chronic use | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Morning or evening, consistent daily |
Possible Side Effects May vary by individual |
|
|
| Research Summary | STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025). | SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda). |
Frequently Asked Questions: Semaglutide vs Liraglutide
What is the difference between Semaglutide and Liraglutide?
Semaglutide is a weight loss peptide that a glp-1 receptor agonist with multiple fda approvals including weight loss, t2d, cv risk reduction, and kidney protection. wegovy pill approved dec 2025 as first oral glp-1 for weight loss. Liraglutide is a weight loss peptide that an fda-approved glp-1 receptor agonist for type 2 diabetes and chronic weight management. the predecessor to semaglutide with daily dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Liraglutide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Liraglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Liraglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Liraglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.